BioCentury | Jul 28, 2014
Finance

Highlights of weekly biotech stock moves

...of 4 million shares at $5.50 in a follow-on. Earlier in the month, CymaBay (formerly Metabolex Inc....
BioCentury | Jul 23, 2014
Financial News

CymaBay raises $22 million in follow-on

...with data expected in 1H15. The compound is a uricosuric agent. Last week, CymaBay (formerly Metabolex Inc....
BioCentury | Jul 21, 2014
Finance

Highlights of weekly biotech stock moves

...before CymaBay announced the amendment, the company would raise $21.1 million. In April, CymaBay (formerly Metabolex Inc....
BioCentury | Jul 21, 2014
Financial News

CymaBay amends follow-on

...amended its follow-on and now plans to sell 3.5 million shares. In April, CymaBay (formerly Metabolex Inc....
BioCentury | Jul 18, 2014
Financial News

CymaBay amends follow-on

...million. Cowen; Stifel; Roth Capital Partners; and National Securities are underwriters. In April, CymaBay (formerly Metabolex Inc....
BioCentury | Apr 14, 2014
Financial News

CymaBay proposes follow-on

...Partners; National Securities Note: CymaBay also plans to transfer its listing to NASDAQ. CymaBay (formerly Metabolex Inc....
BioCentury | Apr 10, 2014
Financial News

CymaBay to raise $30 million, move to NASDAQ

...listing to NASDAQ. Cowen; Stifel; Roth Capital Partners; and National Securities are underwriters. CymaBay (formerly Metabolex Inc....
BioCentury | Dec 12, 2013
Financial News

CymaBay raises $35.2 million

...of a $10 million loan from Oxford Finance and Silicon Valley. In October, CymaBay (formerly Metabolex Inc....
BioCentury | Nov 5, 2012
Strategy

Racing to rebuild AZ

...two Phase III trials, with initial data expected in 1Q14. Arhalofenate, another URAT1 inhibitor from Metabolex Inc....
...NYSE:JNJ), New Brunswick, N.J. The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. MedImmune LLC , Gaithersburg, Md. Metabolex Inc....
BioCentury | Jul 9, 2012
Strategy

Triple play in diabetes

...the next stage of development. The most advanced GPR119 agonists are PSN821 and MBX-2982 from Metabolex Inc....
...Intercept Pharmaceuticals Inc. , New York, N.Y. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Metabolex Inc....
Items per page:
1 - 10 of 152
BioCentury | Jul 28, 2014
Finance

Highlights of weekly biotech stock moves

...of 4 million shares at $5.50 in a follow-on. Earlier in the month, CymaBay (formerly Metabolex Inc....
BioCentury | Jul 23, 2014
Financial News

CymaBay raises $22 million in follow-on

...with data expected in 1H15. The compound is a uricosuric agent. Last week, CymaBay (formerly Metabolex Inc....
BioCentury | Jul 21, 2014
Finance

Highlights of weekly biotech stock moves

...before CymaBay announced the amendment, the company would raise $21.1 million. In April, CymaBay (formerly Metabolex Inc....
BioCentury | Jul 21, 2014
Financial News

CymaBay amends follow-on

...amended its follow-on and now plans to sell 3.5 million shares. In April, CymaBay (formerly Metabolex Inc....
BioCentury | Jul 18, 2014
Financial News

CymaBay amends follow-on

...million. Cowen; Stifel; Roth Capital Partners; and National Securities are underwriters. In April, CymaBay (formerly Metabolex Inc....
BioCentury | Apr 14, 2014
Financial News

CymaBay proposes follow-on

...Partners; National Securities Note: CymaBay also plans to transfer its listing to NASDAQ. CymaBay (formerly Metabolex Inc....
BioCentury | Apr 10, 2014
Financial News

CymaBay to raise $30 million, move to NASDAQ

...listing to NASDAQ. Cowen; Stifel; Roth Capital Partners; and National Securities are underwriters. CymaBay (formerly Metabolex Inc....
BioCentury | Dec 12, 2013
Financial News

CymaBay raises $35.2 million

...of a $10 million loan from Oxford Finance and Silicon Valley. In October, CymaBay (formerly Metabolex Inc....
BioCentury | Nov 5, 2012
Strategy

Racing to rebuild AZ

...two Phase III trials, with initial data expected in 1Q14. Arhalofenate, another URAT1 inhibitor from Metabolex Inc....
...NYSE:JNJ), New Brunswick, N.J. The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. MedImmune LLC , Gaithersburg, Md. Metabolex Inc....
BioCentury | Jul 9, 2012
Strategy

Triple play in diabetes

...the next stage of development. The most advanced GPR119 agonists are PSN821 and MBX-2982 from Metabolex Inc....
...Intercept Pharmaceuticals Inc. , New York, N.Y. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Metabolex Inc....
Items per page:
1 - 10 of 152